What question did this study set out to answer?

This research evaluates the effectiveness of biologic therapies in treating severe asthma with type 2 inflammation and identifies factors for optimal patient selection.

February 22, 2026

Biologic Therapies for Severe Asthma with Type 2 Inflammation: Current Evidence, Patient Selection, and Future Perspectives

Key Points

This research evaluates the effectiveness of biologic therapies in treating severe asthma with type 2 inflammation and identifies factors for optimal patient selection.
Review of current literature on biologic agents for allergic asthma.
Analysis of personalized medicine approaches for treatment
Assessment of patient selection criteria and disparities.
Biologic therapies show significant clinical benefits in patients with type 2 inflammation.
Personalized medicine enhances treatment efficacy and improves patient outcomes.
Further research is needed to refine patient selection and expand therapeutic strategies.

Abstract

Biologic agents targeting type 2 inflammation represent a paradigm shift in allergic asthma treatment. Personalized medicine approaches maximize clinical benefits, though continued research is essential to refine patient selection criteria, address disparities, and extend therapeutic options.

Bookmark

Biologic Therapies for Severe Asthma with Type 2 Inflammation: Current Evidence, Patient Selection, and Future Perspectives

Key Points

Abstract

Cite This Study

Also Consider

Also Consider